For many people in less developed countries, gaining access to healthcare is a problem. They lack of effective and affordable medicines, trained personnel who know which medicines to administer, clean drinking water, and the infrastructure for distribution.
These are challenges that call for support from pharmaceutical companies. Every two years, the Access to Medicine Foundation publishes an index that evaluates to what extent the world’s largest pharmaceutical companies are successfully meeting these challenges. In the 2016 Index, our company came in fourth. This result means we have moved up two places since the last ranking.
The Access to Medicine Foundation has especially recognized us for providing Minilabs
in less developed countries to detect counterfeit medicines, supporting local pharmaceutical companies with our expertise, furthering vaccine production locally, closing the gaps in the healthcare infrastructure in rural areas of India through the Su-Swastha and Swasthya Yatra projects, and managing our intellectual property situation transparently.
Our Praziquantel Donation Program
, which we are pursuing in cooperation with the World Health Organization to eliminate the dangerous tropical disease schistosomiasais, was also evaluated by the Access to Medicine Index, as were our activities to curb the spread of the Zika virus in Latin America as well as to develop a test kit
to detect HIV/AIDS in blood.